Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
- 29 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 80 (12), 1169-1181
- https://doi.org/10.1007/s40265-020-01327-7
Abstract
Immune checkpoint inhibitors (ICIs) in combination with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have become a new standard of care in treatment-naïve patients with advanced renal cell carcinoma (RCC). The rationale for these combinations relies on the interplay between the immune and angiogenic systems. The angiogenic factors and their receptors can promote an immunosuppressive tumor microenvironment by a direct effect on the innate immune cells and adaptive immune cells, and by an indirect effect through their influence on endothelial cells. Antiangiogenic therapies counteract these immunosuppressive effects by increasing tumor infiltration of mature dendritic cells and effector T cells, and decreasing tumor infiltration of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. The immunomodulatory properties of antiangiogenic therapies combined with ICIs may provide enhanced activity through various mechanisms of action. Different associations with ICIs such as programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors and antiangiogenic therapies such as VEGFR-TKI or bevacizumab have been tested and led to the approval of pembrolizumab plus axitinib and avelumab plus axitinib in the first-line treatment of patients with advanced RCC. Other VEGFR axis inhibitors and ICI combinations are currently being tested with promising results. More combinations of immune agents, including cancer vaccines and immunostimulatory agents, are also being evaluated in association with VEGFR-TKI. Defining the best combination for each patient as well as the optimal therapeutic sequence will be essential to guide treatment decisions in clinical practice.Keywords
This publication has 104 references indexed in Scilit:
- Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growthThe Journal of Experimental Medicine, 2012
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyProceedings of the National Academy of Sciences of the United States of America, 2012
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyInternational Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeting immune suppressing myeloid-derived suppressor cells in oncologyCritical Reviews in Oncology/Hematology, 2011
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010
- Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasionThe Journal of Experimental Medicine, 2010
- Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functionsHuman Immunology, 2009
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytesBritish Journal of Cancer, 2009
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996